TwinStrand Biosciences, founded in Seattle, focuses on revolutionizing DNA sequencing with its proprietary Duplex Sequencing technology. The company's core mission is to enable faster and more accurate life-saving decisions for physicians, patients, and drug researchers. TwinStrand offers a range of products and services, including AML assays, mutagenesis assays, nitrosamine testing, and custom sequencing solutions. Their market focus spans healthcare providers, pharmaceutical companies, and research institutions.
Notable figures affiliated with TwinStrand Biosciences include key investors and advisors from leading biotech and genomics fields. The company has achieved significant milestones, such as the publication of groundbreaking research on measuring minimal residual disease (MRD) in acute myeloid leukemia (AML). TwinStrand's impact is evident in its contributions to enhancing the precision of genetic testing and advancing personalized medicine.
